Evotec and Merck sign agreement

Published: 19-Jan-2002


Evotec OAI has entered into an agreement with Merck & Co to synthesise small molecule chemical libraries. Under the terms of the agreement, Evotec OAI will synthesise well-characterised drug-like library compounds using its proprietary high-speed combinatorial chemistry and auto-purification platforms Merck will use these compounds in its drug research and development programmes.

'We believe that Evotec OAI's proprietary technology platforms will uniquely contribute to our compound acquisition programme,' said Thomas Salzmann, senior v p basic research, Merck.

You may also like